Epidemiology, clinical presentation and outcome of human mpox in Rivers State, Nigeria during the 2022-23 outbreak: an observational retrospective study

2022-2023年尼日利亚河流州人痘疫情的流行病学、临床表现和预后:一项观察性回顾性研究

阅读:1

Abstract

INTRODUCTION: limited studies describe the epidemiology, clinical presentation, and outcome of mpox in Rivers State, Nigeria. METHODS: an observational retrospective study of suspected mpox cases seen between October 21, 2021, and April 30, 2023, at the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria. Laboratory confirmation was by qPCR testing of skin swabs, or crust samples. A data extraction form was used to obtain sociodemographic and clinical data. The primary outcome was the rate of hospitalization and death. Data was analyzed using IBM SPSS version 25. A p-value of <0.05 was considered statistically significant. RESULTS: of 35 participants, 24 (68.6%) were males with a mean age [standard deviation] of 33.7 (± 9.9 years), and 5 (14.3%) had HIV infection. The majority (n=33, 94.3%) reported being in a heterosexual relationship with a household identified as the probable place of contact (n=13, 72.2%). None of the patients reported contact with animals or a travel history. The most common symptoms were skin rash (35, 100%), followed by fever (26, 74.3%), and fatigue (26, 74.3%). Concomitant varicella zoster virus infection (n=6, 17.1%), hospital admission (n=28, 80%), and death (n=3, 8.6%) were observed. There was a statistically significant association between mortality and patients with HIV (p = 0.002). CONCLUSION: the 2022-23 mpox outbreak in Rivers State predominantly affected young adults and was characterized by human-to-human transmission and typical febrile rash syndrome with an association between mpox mortality and HIV infection. Targeted public health interventions are needed to control the spread of mpox in Nigeria.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。